SCM
DSGN icon

Soleus Capital Management’s Design Therapeutics DSGN Stock Holding History

Soleus Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,025,000
Closed -$2.42M – 85
2023
Q3 		$2.42M Buy
+1,025,000
New +$4.78M 0.22% 67

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Soleus Capital Management's DSGN Position: Q4 2023 in Review

Soleus Capital Management sold out of Design Therapeutics (DSGN) in Q4 2023, closing a stake of 1,025,000 shares — an estimated $2.42M sold.

Soleus Capital Management first reported a position in DSGN in Q3 2023 and held it in 1 quarter. The position peaked at $2.42M in Q3 2023. 88 funds tracked by Wall St. Rank hold DSGN as of Q4 2023.

  • Soleus Capital Management reported no remaining Design Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Soleus Capital Management sold 1,025,000 Design Therapeutics shares in Q4 2023, an estimated $2.42M.
  • Soleus Capital Management first reported a position in Design Therapeutics in Q3 2023 and held it in 1 quarter.
  • Soleus Capital Management's Design Therapeutics position peaked at $2.42M in Q3 2023.
  • 88 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2023.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.